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CHLOROQUINE-RESISTANT PLASMODIUM VIVAX IN TRANSMIGRATION
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U.S. Naval Medical Research Unit No. 2, Jakarta, Indonesia; National Institute for Health Research, Jakarta, Indonesia;
Provincial Department of Health, Pontianak, West Kalimantan, Indonesia; District Health Office, Ketapang,
West Kalimantan, Indonesia; Department of Medicine, University of Toronto, Toronto, Ontario, Canada;
Naval Medical Research Institute, Rockville, Maryland
Abstract. Malariometric surveys were conducted during July 1996 in native Dayak villages and predominantly
Javanese transmigration settlements in Ketapang district of West Kalimantan, Indonesia. Malaria prevalence ranged
from 0.9% to 2.7% in Dayak villages and from 1% to 20% in the transmigration settlements. Plasmodium falciparum
accounted for 67% of the cases among Dayaks but P. vivax was dominant among transmigrants, accounting for more
than 72% of the infections. Chloroquine sensitivity/resistance was assessed by 28-day in vivo testing of uncomplicated
malaria infections and measurement of chloroquine blood levels in cases where parasitemias reappeared within the
28-day test period. Resistance was based on the appearance of asexual parasites against chloroquine plus desethylchlo-
roquine levels exceeding the minimally effective whole blood concentrations proposed for sensitive parasite strains
(P. vivax, 100 ng/ml; P. falciparum, 200 ng/ml). All parasitemias cleared initially within four days of beginning
supervised chloroquine therapy (25 mg base/kg over a 48-hr period), but asexual parasites reappeared within 28 days
in 27 of 52 P. vivax and three of 12 P. falciparum cases. Chloroquine blood levels at the time of recurrent parasitemias
revealed resistance in 12 of the 27 P. vivax cases and in one of the three P. falciparum cases. Genotypes of nine of
the 12 recurrent P. vivax isolates matched with their primary isolates and ruled out reinfection. These findings establish
the presence of chloroquine-resistant P. vivax on the island of Borneo. The pattern of malaria and the high frequency
of chloroquine resistance by P. vivax at the West Kalimantan location may relate to demographic, ecologic, agricul-
tural, and socioeconomic changes associated with transmigration.
Chloroquine has long been the world’s standard effective
drug for prevention and treatment of vivax malaria, but re-
sistance appears to be an emerging problem in the Indo-
Pacific region that may have already spread globally. The
first report of clinical resistance came from Papua New
Guinea in 19891 followed by successive reports of chloro-
quine-resistant vivax malaria from Irian Jaya,2–5 Myanmar,6,7
India,8 Sumatra,9 and Sulawesi.10 In the New World, chlo-
roquine-resistant Plasmodium vivax has been described in
Guyana.11
Key to making a definitive pronouncement of in vivo re-
sistance to therapeutic levels of chloroquine is strict super-
vision of the appropriate dose, careful follow-up to monitor
parasitemia, and demonstration of chloroquine blood levels
at the time of an unremitting or recurrent parasitemia in ex-
cess of the minimally effective concentrations (MECs) es-
tablished for sensitive strains of the malaria parasites (. 100
ng/ml for P. vivax; . 200 ng/ml for P. falciparum). Genetic
fingerprinting can also determine whether recurrent infec-
tions arise from recrudescence/relapse of the primary infec-
tion or from a separate inoculation. These stringent criteria
and the methodologies they entail are not easily met and
definitive reports of chloroquine-resistant P. vivax have been
slowly forthcoming. A systematic effort has been underway
to detect and measure the occurrence of this problem in In-
donesia. This report describes studies conducted among na-
tive Pesaguan Dayaks and non-indigenous transmigrants in
West Kalimantan (Borneo), Indonesia using an in vivo test
format developed at this laboratory.12 Results are presented
of in vivo tests for chloroquine sensitivity/resistance, drug
levels, and selective parasite genotyping from among the in-
fected subjects that were treated.
SUBJECTS AND METHODS
Study site. Kalimantan is the Indonesian name given to
the island widely known as Borneo. This study was focused
in West Kalimantan province, Indonesia at Ketapang (28S,
1108E), the largest and southernmost district of the province,
with an area of 35,809 km2 and an estimated population of
361,000. This district does not have abundant realized min-
eral and timber resources, but its climate and vast lowlands
are suited to rubber and oil palm cultivation and large plan-
tations; some in excess of one million hectares have been
established. The development and production of these plan-
tation industries have required more individuals than have
been locally available and the Indonesian Ministry of Trans-
migration has settled thousands of landless families from
crowded parts of Indonesia into Ketapang for this purpose.
Government figures show that during fiscal year 1995 more
transmigrants were settled into West Kalimantan than into
any other province of Indonesia (33,012 of 112,069), and
that the majority of these West Kalimantan transmigrants
(16,081 of 33,012) were settled into Ketapang District (In-
donesian Ministry of Transmigration and Resettlement,
1996, unpublished data). Most of these transmigrants
(86.5%) were young, subsistence-level farmers from the rel-
atively malaria-free provinces of Java. Families from the
more malarious eastern provinces of West Nusa Tenggara
and East Nusa Tenggara comprised the remaining 13.5%.
Approximately half of the houses in Ketapang transmigra-
tion settlements are allocated to translocal Dayak families,
but many of these indigenous people also maintain residence
in their traditional villages.
Malaria is second only to respiratory infection as the most
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frequently diagnosed acute illness in West Kalimantan prov-
ince, accounting for 27% of all cases of infectious illness
seen in health clinics during 1995. Annual incidence of clin-
ical malaria ranged from three (Pontianak) to 44 (Sintang)
cases/1,000 residents in the seven administrative districts of
the province and averaged 15 cases/1,000 in Ketapang. Ma-
lariometric survey by active case detection during 1995 re-
vealed that malaria point prevalence ranged from 0% (Pon-
tianak) to 16% (Kapuas Hulu) and was 12.4% in Ketapang
(West Kalimantan Department of Health, 1996, unpublished
data). Entomologic surveys have identified 13 different an-
opheline species in West Kalimantan (Anopheles letifer, An.
lesteri, An. umbrosus, An. leucosphyrus, An. tesselatus, An.
baezai, An. nigerrimus, An. sinensis, An. barbirostris, An.
balabacensis, An. kochi, An. sundaicus, and An. peditaen-
iatus) of which An. letifer, An. sundaicus, An. balabacensis,
An. barbirostris, An. nigerrimus, and An. leucosphyrus13–16
have been incriminated or reported as vectors of malaria on
the island of Borneo. Human bait collections have reportedly
captured An. nigerrimus and An. sinensis from within trans-
migration settlements (Ketapang Department of Health, un-
published data). Recent larval collections from rice paddies,
streams, and weed-choked ditches at these sites have yielded
only An. nigerrimus and An. peditaeniatus (Fryauff DJ, un-
published data).
Study subjects. All residents of four Dayak villages (Batu
Tajam I, Batu Tajam II, Marau Sinar Bulan, Sei Melayu) and
five transmigrant settlements (SP-4, -5, -6, -7, and Lalang
Panjang) were invited to undergo parasitologic screening for
malaria by submitting a drop of blood for thick and thin film
preparation. The average residence time in West Kalimantan
for inhabitants of the five transmigration settlements was
three months, six months, three years, four months, and five
years, respectively. Individuals from these screenings who
were $ 5 years old, had uncomplicated malaria, were able
to swallow chloroquine tablets, and who had used no anti-
malarial drug in the previous week were invited to volunteer
for the 28-day in vivo test. Written informed consent was
obtained from the subject/parent and a description of all
complaints associated with the infection was verbally elic-
ited.
This work was conducted in accordance with U.S. Navy
and Republic of Indonesia regulations governing the protec-
tion of human subjects in medical research. American and
Indonesian committees for the protection of human subjects
reviewed and approved the procedures followed in this re-
search.
Chemotherapy and follow-up. The first-line treatment
for all clinical malaria cases in Indonesia is standard chlo-
roquine therapy combined with a 15 mg dose of primaquine
on the first day. Chloroquine therapy is combined with a
five-day regimen of primaquine for confirmed P. vivax in-
fections. If there is no clinical improvement within the first
2–3 days, chloroquine therapy is repeated with a 14-day reg-
imen of primaquine.17 Primaquine was omitted from the ma-
laria treatments described here to yield valid in vivo assess-
ments of P. vivax sensitivity/resistance to chloroquine alone.
Combined chloroquine and primaquine have been shown to
work additively or synergistically against chloroquine-resis-
tant strains of malaria parasites.18,19
Enrolled study subjects were administered 25 mg of chlo-
roquine (Resochint, P. T. Bayer, Jakarta, Indonesia) base/kg
of body weight as 10 1 10 1 5 mg/kg doses at 24-hr inter-
vals. Consumption of each dose was witnessed by a member
of the study team and physical complaints were recorded at
the time of each visit. Study subjects were advised to take
no other drugs but those provided to them by the study team
and to immediately report any incident of drug reaction or
heightened/recurrent malaria symptoms to an on-site team
member. Thick and thin blood films were made on days 0,
2, 4, 7, 11, 14, 18, 21, and 28, or on any occasion of malaria-
like illness. Giemsa-stained blood films were examined by
light microscopy (oil-immersion 1,0003 magnification) and
considered negative if no asexual parasites were detected in
300 ocular fields of the thick film. Parasite counts/200 white
blood cells were multiplied by a factor of 40 to estimate the
parasite count/ml of blood. Standard sulfadoxine plus pyri-
methamine or quinine therapy was provided for all unremit-
ting or recurrent symptomatic infections.
Chloroquine levels in whole blood. Whole blood aliquots
of 100 ml were collected by a heparinized capillary from
fingersticks on days 0, 2, and 28, or on the day of a recurrent
asexual stage parasitemia. This blood was blotted onto a disk
of Whatman No. 1 filter paper (Whatman International Ltd.,
Maidstone, United Kingdom) and air-dried, with care taken
to prevent contamination with chloroquine residues in the
air or on fingers. In our Jakarta laboratory, the parent com-
pound chloroquine and its major active metabolite desethyl-
chloroquine were extracted with polar solvent according to
published methods.20 Quantitative analysis of extracts was
performed by means of high-performance liquid chromatog-
raphy (HPLC) using a Bio-Rad model 2700 solvent delivery
system, a Bio-Sil Polyol 90-10 column (Bio-Rad Laborato-
ries, Inc., Melville, NY), and a model 1311 flouroMonitory
III analyzer (LDC Analytical, Riviera Beach, FL) interfaced
with an IBM (Yorktown Heights, NY) compatible desktop
computer via Microsoft (Redmond, WA) Windows 3.0 and
version 2.3 HPLC software (Bio-Rad) software. Clean mo-
bile phase recycling was integrated into the system via an
IRS 1000 integrated recovery system for liquid chromatog-
raphy (Jones Chromatography USA, Inc., Lakewood, CO),
and an internal standard of isopropyl chloroquine was used
for calibration. In accordance with current survey methods,
resistance to chloroquine therapy was based upon the ap-
pearance of a post-therapeutic asexual stage parasitemia
against whole blood levels of chloroquine/desethylchloro-
quine . 100 ng/ml for P. vivax or . 200 ng/ml for P. fal-
ciparum.12
Genetic fingerprinting of primary and failure isolates
of P. vivax. The DNA was extracted from whole blood sam-
ples of paired primary and failure infections. Portions of the
genes coding for the merozoite surface protein-1 and the
circumsporozoite protein were amplified by polymerase
chain reaction (PCR) using oligonucleotide primers synthe-
sized to conserved sequences flanking the variable regions.
The paired primary and failure PCR products were analyzed
by single-stranded conformational polymorphism (SSCP) ac-
cording to published methodology.11 Isolates from treatment
failures were considered to be clones of the primary infec-
tion if the SSCP pattern of the failure isolate was the same
as or contained within the SSCP pattern of the primary iso-
late.
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TABLE 1
Malaria point prevalence by species and age group among transmigrants and native Dayaks in Ketapang District, West Kalimantan, Indonesia,
July–August 1996*
Age group
(years)
Transmigrants
No. tested No. P.f. No. P.v.
Native Dayaks
No. tested No. P.f. No. P.v.
,2
2–5
6–10
11–15
124
270
212
85
0
3 (1g)†
5 (3g)
1
0
6 (1g)
13 (1g)
9 (4g)
35
114
109
67
1
3 (2g)
2 (2g)
1
0
1
1
2
16–25
25–40
.40
Total
314
405
40
1,450
6 (4g)
5 (3g)
0
20 (1.4%)
8 (3g)
13 (5g)
3 (3g)
52 (3.6%)
113
186
134
758
0
2 (1g)
1
10 (1.3%)
0
0
2‡ (1g)
6 (0.8%)
* P.f. 5 Plasmodium falciparum; P.v. 5 P. vivax.
† (g) denotes number of cases with gametocytes.
‡ One mixed P. falciparum 1 P. vivax infection.
TABLE 2
Summary of 28-day in vivo test results for chloroquine sensitive/resistant malaria in transmigration settlements of Ketapang, West Kalimantan,
Indonesia, July–August 1996 (95% confidence intervals are given in parentheses)
Characteristic Plasmodium falciparum Plasmodium vivax
Number tested
Age (years)
Hemoglobin (mg/dL of blood)
GM* parasitemia (/ml of blood)
12
25.2 (18.3–32.2)
10.4 (9.2–11.5)
440 (139–1,390)
52
24.7 (21.1–28.3)
9.6 (9.3–10.0)
803 (525–1,228)
CI† of therapeutic failure
Day 7
Day 14
Day 21
Day 28
0
8.3% (11)
16.5% (11)
25% (11)
1.9% (11)
5.8% (12)
34.6% (115)
51.9% (19)
Drug‡ levels (ng/ml of blood)
Day 0
Day 2
Day of recurrence
24§
911 (687–1,133)
205
17¶
940 (807–1,073)
203 (156–251)
* Geometric mean parasitemia.
† Cumulative incidence of recurrent parasitemias.
‡ Mean ng/ml of chloroquine (CQ) 1 desethylchloroquine (DCQ).
§ CQ only detected in 5 of 12 subjects at enrollment.
¶ CQ only detected in 14 of 52 subjects; CQ 1 DCQ detected in 3 of 52 subjects at enrollment.
RESULTS
Malaria prevalence. A total of 758 ethnic Dayaks and
1,450 predominantly Javanese transmigrants were screened
for malaria infection. Screening prevalence ranged from
0.9% to 2.7% in the four Dayak villages (Sei Melayu, 0.9%;
Batu Tajam II, 1.2%; Marau Sinar Bulan, 2.0%; and Batu
Tajam I, 2.7%) and falciparum malaria accounted for 10 of
the 15 cases identified in this population (67%). Malaria
prevalence ranged from 1.0% to 20.0% in the five transmi-
grant settlements (SP-7, 1.0%; SP-5, 1.2%; SP-4, 1.7%; SP-
6, 5.8%; and Lalang Panjang, 20.0%), and vivax malaria
accounted for 72.2% of the 72 cases identified. The highest
prevalence occurred in the oldest transmigrant settlement
where numerous rice paddies and fish ponds had been es-
tablished. Table 1 shows the proportions of malaria infection
by species and age group in the two populations. In both
populations, the majority of infections were found in chil-
dren 2–15 years old (Dayaks, 10 of 15 5 67%; transmi-
grants, 37 of 72 5 51.4%). The prevalence of malaria in
transmigrant children 2–15 years old (37 of 567 5 6.5%)
and adults . 15 years old (35 of 759 5 4.6%) was com-
parable (P 5 0.16); however, malaria prevalence in Dayak
children 2–15 years old (10 of 290 5 3.4%) was significantly
greater (P 5 0.03) than that of Dayak adults .15 years old
(4 of 433 5 0.9%). Overall, malaria prevalence in transmi-
grants (72 of 1,450 5 5.0%) was significantly greater (P ,
0.001) than in Dayaks (15 of 758 5 2.0%).
In vivo sensitivity/resistance. Table 2 shows the results
of 28-day in vivo tests for chloroquine sensitivity/resistance
conducted with 12 cases of falciparum and 52 cases of vivax
malaria from the surveyed populations of Batu Tanjam (n 5
2), SP-5 (n 5 3), SP-6 (n 5 20), SP-7 (n 5 1), and Lalang
Panjang (n 5 39). Three subjects, one with P. falciparum,
and two with P. vivax, were disenrolled after the first day of
therapy because of presumed allergic reaction to chloroquine
(urticaria) and were provided alternative treatment with sul-
fadoxine/pyrimethamine. All 12 P. falciparum parasitemias
decreased more than 75% by the last day of therapy (day 2)
and asexual stages were absent by day 4. Gametocytes ap-
peared unaffected and consistently present through follow-
up in five cases. Trophozoites reappeared in two of the 12
cases on days 11 and 18. Whole blood levels of chloroquine
plus desethylchloroquine on these days were 186 ng/ml and
205 ng/ml, respectively. One asymptomatic parasitemia ap-
peared on day 28 with an undetectable low blood level of
chloroquine.
All 52 parasitemias by P. vivax decreased by more than
75% within the first 48 hr of receiving chloroquine. Parasite
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clearance was achieved by day 2 in 72% of the cases and
by day 4 in 98%. Trophozoites in steadily reducing numbers
remained through day 4 in one case but cleared by day 7
and remained absent through the remaining three weeks of
follow-up. Trophozoites reappeared between seven and 28
days post-therapy in 52% (27) of the P. vivax cases (Table
1). Gametocytes, present at the start of treatment in 31.4%
of the P. vivax cases, disappeared with treatment and did not
reappear within the 28 days of follow-up in any subject.
Whole blood levels of chloroquine measured at the time of
each recurrence (reinfection/recrudescence/relapse) ranged
from 0 to 411 ng/ml. Fifteen parasitemias appeared between
test days 18 and 28 against whole blood levels of chloro-
quine plus desethychloroquine less than 100 ng/ml. Drug
levels in 12 cases that recurred from seven to 21 days post-
treatment (mean 5 17 days) were above this MEC. Geno-
typic fingerprints of primary and failure isolates, which
matched in eight of these cases, ruled out reinfection and
indicated true treatment failure. The other four pairs were
mismatches as a result of either insufficient DNA from the
drug-resistant clone in the primary infection or reinfection.
Whole blood chloroquine plus desethychloroquine levels in
vivax malaria subjects measured on day 2, after the first two
doses of chloroquine, ranged from 187 to 2,095 ng/ml (mean
5 940 ng/ml), with a 95% confidence interval around this
mean of 807–1,072 ng/ml. There was no significant corre-
lation between low day 2 drug levels and early recurrence
of parasitemia (r 5 0.16, P 5 0.22). Low drug absorption,
indicated by day 2 levels of chloroquine plus desethychlor-
oquine less than 500 ng/ml, was seen in seven subjects and
parasitemias appeared within the 28-day follow-up period
(days 14, 18, 18, 18, and 28) in five of these cases.
DISCUSSION
These survey results revealed distinct demographic pat-
terns of malaria occurring in Ketapang District of West Ka-
limantan, Indonesia, and an unexpectedly high frequency of
chloroquine resistance in P. vivax. The overall higher prev-
alence rate of malaria among transmigrants was not surpris-
ing. Most of these people came from the crowded provinces
of Java where the incidence of malaria has been estimated
to be less than two cases per 10,000 person-years since
1965,21 and were thus highly vulnerable to infection and
clinical symptoms. Indonesia’s transmigration settlements
are sited by design in the underpopulated and underdevel-
oped frontier provinces of the nation, and plans for each
location allocate up to half of the new houses for members
of the local ethnic population. This cross-cultural mixing is
intended to introduce transmigrants to appropriate cultural
practices and agricultural techniques, while benefiting the
indigenous people with jobs, schools, places of worship, and
a variety of government services that were previously be-
yond their reach. This blending inadvertently brings game-
tocyte carriers into proximity with the malaria naive new-
comers and may be partly responsible for explosive out-
breaks that occur each year.22 However, this scenario was not
evident in Ketapang. Although half of the houses in each
Ketapang transmigration settlement were allocated to local
Dayak families, many of these houses were vacant and Day-
aks, if present, did not participate in our open malaria
screenings. Moreover, survey within Dayak communities
showed low malaria prevalence. It seems possible that the
nuclei of infection in Ketapang transmigration settlements
may have arisen from among the transmigrants themselves;
possibly from among the hundreds of families that immi-
grated from the more malarious provinces of eastern Indo-
nesia. Recent screening of 260 apparently healthy school-
children from a populous district in East Nusa Tenggara
(Sikka, Flores Island) showed the malaria prevalence to be
40% (Fryauff DJ, unpublished data). While chloroquine re-
sistance characterizes more than 70% of P. vivax cases
among transmigration settlements in Irian Jaya,18,22–24 it is not
yet known whether there are also significant pools of chlo-
roquine-resistant P. vivax circulating in the nearby provinces
of East Nusa Tenggara and West Nusa Tenggara.
Environmental and cultural factors are believed to have
also strongly determined the different patterns of malaria
transmission at our survey sites. Dayak communities were
long-established, traditional villages situated within or at the
fringe of secondary forest. Their houses were more densely
clustered than those of the transmigrant settlement, domestic
animals were abundant, and their villages were well-shaded
by diverse species of mature trees. Dayak villages also ap-
peared to be well drained, due to their placement along
swiftly flowing streams and rivers. A highly conspicuous,
and perhaps critical difference between transmigrant and na-
tive communities was the Dayak’s tendency to distance their
rice paddies from their homes and to grow rice by shifting
cultivation in naturally occurring swamp areas. In contrast,
the radically altered environment of the young palm plan-
tation and its new settlements eliminated the original diverse
populations of flora and fauna and opened the land to almost
unchecked colonization by a relative few mosquito species.
In the absence of either wild or domestic animals, humans
are virtually the only source of blood feeding by mosquitoes
in the new settlements. Anopheles nigerrimus, which was
collected as larvae from rice paddies and irrigation ditches
within the Lalang Panjang settlement, has been responsible
for localized malaria outbreaks when it proliferates in close
proximity to large human populations and when domestic
animal blood sources are scarce.13 The vectorial status of An.
peditaeniatus, found in the same breeding habitats as An.
nigerrimus, is unknown, but both of these species are con-
sidered predominantly zoophilic and breed preferentially in
rice paddies and open freshwater habitats exposed to the
sun.14
Bed nets, chloroquine prophylaxis for the first 90 days,
and insecticide (bendiocarb) spraying of the interior walls of
each house are important government efforts that are rou-
tinely made to protect the new transmigrants.18,25,26 While
these measures were insufficient to prevent the early and
explosive malaria outbreaks seen in transmigration settle-
ments of Irian Jaya,22 they may be effective during the first
year in Ketapang where different transmission dynamics pre-
vail and are only overcome in subsequent years when exten-
sive rice cultivation and irrigation systems increase and sta-
bilize the anopheline vector populations. This phenomenon
of delayed malaria outbreak has also been observed and re-
ported for the Satai transmigration settlement of West Kali-
mantan.26 In the more established transmigration settlements
(SP-4, 3 years; Lalang Panjang, 5 years), night time electri-
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cal supply facilitates social gatherings during the peak hours
of vector activity. The growing popularity of open air, night
time television viewing in these communities serves to in-
form and educate the people but also plays an unfortunate
role in heightening malaria transmission. It is repeatedly ob-
served that privately owned televisions, when offered for
community viewing each night, become potent lures that
draw people, mainly children, out into the night and increase
their risks of acquiring malaria.
In vitro test results have identified chloroquine-resistant
falciparum malaria in each of Indonesia’s 27 provinces,27 but
this drug remains the first line of treatment for clinical ma-
laria at each of the four levels of the national health service.
Full appropriate chloroquine treatment dosages can be pro-
vided at each level when the drug is in stock, but outside
the clinic strict compliance with the treatment regimen can-
not be ensured, and it is probable that many people who feel
improvement after the first 600-mg dose do not take the
second and third, choosing to save the pills for another oc-
casion. In Ketapang transmigration settlements, the local ki-
osks are a reliable source of chloroquine, which is sold in
packaged units of four pills, each pill containing 150 mg
base, for US $0.44/package. An adult transmigrant must pur-
chase three packages at an equivalent cost of US $1.32 to
obtain sufficient pills for a full standard therapy of 1,500 mg
base; a cost equal to half of his or her daily wage in the oil
palm plantation. These socioeconomic details suggest that
self-treatment with locally purchased chloroquine might typ-
ically involve the use of only one packet of pills, or less
than half of the standard treatment dose. If the drug were
packaged in units of 10 pills, corresponding to the full adult
treatment regimen, packaging costs could be reduced and
savings potentially realized at the user level. Self-treatment
would then at least start with purchase of the correct or ad-
equate dosage of chloroquine. Compliance may be better
when one has no choice but to purchase the full regimen.
In the context of our study, compliance was absolute, and
unambiguous chloroquine resistance accounted for 12 of the
27 P. vivax parasitemias that appeared within the 28-day test
period. Abnormal drug absorption from the start of therapy
is believed to have accounted for an additional five recur-
rences. The remaining 10 parasitemias appeared opportunis-
tically between test days 18 and 28 against low or unde-
tectable chloroquine levels. There is marked individual vari-
ation in the absorption and metabolism of chloroquine.28
Studies in Indonesia have found that the majority of people
given a standard therapeutic dose achieve and then maintain
whole blood levels of chloroquine plus desethychloroquine
greater than the MEC of 100 ng/ml through the 28-day test
period.23,24,29 This was not apparent in our study, in which
the mean day 28 level of chloroquine plus desethychloro-
quine (26.8 ng/ml) following standard treatment was signif-
icantly lower than that of five other ethnic populations in
the region (Fryauff DJ, unpublished data). It seems possible
that variant patterns of chloroquine absorption, metabolism,
and elimination may characterize different racial/ethnic
groups. Similarly, unique dietary or cultural practices, as
well as concurrent enteric infections that reduce intestinal
absorption may alter the usual kinetics of this drug in some
populations and open an earlier window of opportunity for
reinfection, relapse, and/or recrudescence.
In summary, the results indicate that important differences
characterize malaria in native Dayak and transmigrant com-
munities of Ketapang District in West Kalimantan. Demo-
graphic, ecologic, agricultural, and socioeconomic factors
may be responsible for the patterns observed. Insufficient
cases of P. falciparum were found to enable a useful or
conclusive analysis of chloroquine sensitivity or resistance
for this location. However, P. vivax cases were abundant
within transmigration settlements and our unexpected in vivo
test results confirmed chloroquine resistance in 23% of the
cases treated. Within Indonesia, this in vivo testing meth-
odology has only identified sites in Irian Jaya with higher
frequencies of chloroquine resistance by P. vivax.23,24 It is an
interesting coincidence that in both Irian Jaya and Kaliman-
tan, where high frequencies of P. vivax resistance to chlo-
roquine have been documented, the in vivo test subjects at
each site have been predominantly Javanese transmigrants.
These results encourage additional surveys for chloroquine-
resistant vivax malaria among transmigrant communities in
other provinces of Indonesia.
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